EGFR inhibitors for treating disease
Patent Information
- Application Number
- HK62026125110
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-20
- Filing Date
- 2026-06-22
- Publication Date
- 2026-09-11
Abstract
Description
This disclosure relates to compounds that target kinases such as EGFR, pharmaceutical compositions containing said compounds, and methods of treating diseases such as cancer using said compounds. Abstract
Claims
WHAT IS CLAIMED IS:
1. A compound of the formula Iwherein ring A and ring B are each independently a 5-membered heteroarylene; each R1and R2, when present, is independently deuterium, halogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, -ORa, -OC(O)Ra, -OC(O)NRaRb, -OS(O)Ra, -OS(O)2Ra, -SRa, -S(O)Ra, -S(O)2Ra, -S(O)NRaRb, -S(O)2NRaRb, -OS(O)NRaRb, -OS(O)2NRaRb, -NRaRb, -NRaC(O)Rb, -NRaC(O)ORb, -NRaC(O)NRaRb, -NRaS(O)Rb, -NRaS(O)2Rb, -NRaS(O)NRaRb, -NRaS(O)2NRaRb, -C(O)Ra, -C(O)ORa, -C(O)NRaRb, -PRaRb, -P(O)RaRb, -P(O)2RaRb, -P(O)NRaRb, -P(O)2NRaRb, -P(O)ORa, -P(O)2ORa, -CN, or -NO2, wherein each hydrogen atom in C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, and 5- to 10-membered heteroaryl is independently optionally substituted by deuterium, halogen, C1-C6alkyl, C1-C6haloalkyl, -ORc, -OC(O)Rc, -OC(O)NRcRd, -OC(=NRd)NRcRd, -OS(O)Rc, -OS(O)2Rc, -OS(O)NRcRd, -OS(O)2NRcRd, -SRc, -S(O)Rc, -S(O)2Rc, -S(O)NRcRd, -S(O)2NRcRd, -NRcRd, -NRcC(O)Rd, -N(C(O)Rc)(C(O)Rd), -NRcC(O)ORd, -NRcC(O)NRcRd, -NRcC(=NRd)NRcRd, -NRcS(O)Rd, -NRcS(O)2Rd, -NRcS(O)NRcRd, -NRcS(O)2NRcRd, -C(O)Rc, -C(O)ORc, -C(O)NRcRd, -C(=NRd)NRcRd,-PRcRd, -P(O)RcRd, -P(O)2RcRd, -P(O)NRcRd, -P(O)2NRcRd, -P(O)ORc, -P(O)2ORc, -CN, or -NO2; each R3, R4, R5, and R6is independently H, deuterium, halogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, -ORa, -OC(O)Ra, -OC(O)NRaRb, -OS(O)Ra, -OS(O)2Ra, -SRa, -S(O)Ra, -S(O)2Ra, -S(O)NRaRb, -S(O)2NRaRb, -OS(O)NRaRb, -OS(O)2NRaRb, -NRaRb,-NRaC(O)Rb, -NRaC(O)ORb, -NRaC(O)NRaRb, -NRaS(O)Rb, -NRaS(O)2Rb, -NRaS(O)NRaRb, -NRaS(O)2NRaRb, -C(O)Ra, -C(O)ORa, -C(O)NRaRb, -PRaRb, -P(O)RaRb, -P(O)2RaRb, -P(O)NRaRb, -P(O)2NRaRb, -P(O)ORa, -P(O)2ORa, -CN, or -NO2, wherein each hydrogen atom in C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10aryl, and 5- to 10-membered heteroaryl is independently optionally substituted by deuterium, halogen, C1-C6alkyl, C1-C6haloalkyl, -ORe, -OC(O)Re, -OC(O)NReRf, -OS(O)Re, -OS(O)2Re, -OS(O)NReRf, -OS(O)2NReRf, -SRe, -S(O)Re, -S(O)2Re, -S(O)NReRf, -S(O)2NReRf, -NReRf, -NReC(O)Rf, -NReC(O)ORf, -NReC(O)NReRf, -NReS(O)Rf, -NReS(O)2Rf, -NReS(O)NReRf, -NReS(O)2NReRf, -C(O)Re, -C(O)ORe, -C(O)NReRf, -PReRf, -P(O)ReRf, -P(O)2ReRf, -P(O)NReRf, -P(O)2NReRf, -P(O)ORe, -P(O)2ORe, -CN, or -NO2; or two of R3, R4, R5, and R6, taken together with the carbon or carbons to which they are attached, combine to form C3-C6cycloalkyl or 3- to 7-membered heterocycloalkyl, wherein each hydrogen atom in C3-C6cycloalkyl and 3- to 7-membered heterocycloalkyl is independently optionally substituted by -ORe, -OC(O)Re, -OC(O)NReRf, -OS(O)Re, -OS(O)2Re, -OS(O)NReRf, -OS(O)2NReRf, -SRe, -S(O)Re, -S(O)2Re, -S(O)NReRf, -S(O)2NReRf, -NReRf, -NReC(O)Rf, -NReC(O)ORf, -NReC(O)NReRf, -NReS(O)Rf, -NReS(O)2Rf, -NReS(O)NReRf, -NReS(O)2NReRf, -C(O)Re, -C(O)ORe, -C(O)NReRf, -PReRf, -P(O)ReRf, -P(O)2ReRf, -P(O)NReRf, -P(O)2NReRf, -P(O)ORe, -P(O)2ORe, -CN, or -NO2; R7is H, deuterium, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, 4- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, -C(O)Rc, or -C(O)NRcRd, wherein each hydrogen atom in C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, 4- to 7-membered heterocycloalkyl, C6-C10 aryl, and 5- to 10-membered heteroaryl is independently optionally substituted by -ORc, -OC(O)Rc, -OC(O)NRcRd, -OC(=NRd)NRcRd, -OS(O)Rc, -OS(O)2Rc, -OS(O)NRcRd, -OS(O)2NRcRd, -SRc, -S(O)Rc, -S(O)2Rc, -S(O)NRcRd, -S(O)2NRcRd, -NRcRd, -NRcC(O)Rd, -N(C(O)Rc)(C(O)Rd), -NRcC(O)ORd, -NRcC(O)NRcRd, -NRcC(=NRd)NRcRd, -NRcS(O)Rd, -NRcS(O)2Rd, -NRcS(O)NRcRd, -NRcS(O)2NRcRd, -C(O)Rc, -C(O)ORc, -C(O)NRcRd, -C(=NRd)NRcRd,-PRcRd, -P(O)RcRd, -P(O)2RcRd, -P(O)NRcRd, -P(O)2NRcRd, -P(O)ORc, -P(O)2ORc, -CN, or -NO2; or R7and one of R3, R4, R5, or R6, taken together with the atoms to which each is attached, combine to form a 4- to 7-membered heterocycloalkyl, wherein each hydrogen atom in 4- to 7-membered heterocycloalkyl is independently optionally substituted by -ORe, -OC(O)Re, -OC(O)NReRf, -OS(O)Re, -OS(O)2Re, -OS(O)NReRf, -OS(O)2NReRf, 0173SRe, -S(O)Re, -S(O)2Re, -S(O)NReRf, -S(O)2NReRf, -NReRf, -NReC(O)Rf, -NReC(O)ORf, -NReC(O)NReRf, -NReS(O)Rf, -NReS(O)2Rf, -NReS(O)NReRf, -NReS(O)2NReRf, -C(O)Re, -C(O)ORe, -C(O)NReRf, -PReRf, -P(O)ReRf, -P(O)2ReRf, -P(O)NReRf, -P(O)2NReRf,-P(O)ORe, -P(O)2ORe, -CN, or -NO2; R8is H, -S(O)2Rc, -S(O)2NRcRd, -C(O)Rc, -C(O)ORc, -C(O)NRcRd, -C(=NRd)NRcRd, -P(O)2RcRd, -P(O)2NRcRd, or -P(O)2ORc; R9is H, deuterium, halogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10aryl, 5- to 10-membered heteroaryl, -ORa, -OC(O)Ra, -OC(O)NRaRb, -OS(O)Ra, -OS(O)2Ra, -SRa, -S(O)Ra, -S(O)2Ra, -S(O)NRaRb, -S(O)2NRaRb, -OS(O)NRaRb, -OS(O)2NRaRb, -NRaRb, -NRaC(O)Rb, -NRaC(O)ORb, -NRaC(O)NRaRb, -NRaS(O)Rb, -NRaS(O)2Rb, -NRaS(O)NRaRb, -NRaS(O)2NRaRb, -C(O)Ra, -C(O)ORa, -C(O)NRaRb, -PRaRb, -P(O)RaRb, -P(O)2RaRb, -P(O)NRaRb, -P(O)2NRaRb, -P(O)ORa, -P(O)2ORa, -CN, or -NO2, wherein each hydrogen atom in C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10aryl, and 5- to 10-membered heteroaryl is independently optionally substituted by deuterium, halogen, C1-C6alkyl, C1-C6haloalkyl, -ORc, -OC(O)Rc, -OC(O)NRcRd, -OC(=NRd)NRcRd, -OS(O)Rc, -OS(O)2Rc, -OS(O)NRcRd, -OS(O)2NRcRd, -SRc, -S(O)Rc, -S(O)2Rc, -S(O)NRcRd, -S(O)2NRcRd, -NRcRd, -NRcC(O)Rd, -N(C(O)Rc)(C(O)Rd), -NRcC(O)ORd, -NRcC(O)NRcRd, -NRcC(=NRd)NRcRd, -NRcS(O)Rd, -NRcS(O)2Rd, -NRcS(O)NRcRd, -NRcS(O)2NRcRd, -C(O)Rc, -C(O)ORc, -C(O)NRcRd, -C(=NRd)NRcRd, -PRcRd, -P(O)RcRd, -P(O)2RcRd, -P(O)NRcRd, -P(O)2NRcRd, -P(O)ORc, -P(O)2ORc, -CN, or -NO2; each Ra, Rb, Rc, Rd, Re, and Rfis independently selected from the group consisting of H, deuterium, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, C1-C6alkylene-C6-C10 aryl, 5- to 10-membered heteroaryl, and C1-C6alkylene-5- to 10-membered heteroaryl; or Raand Rbor Rcand Rdor Reand Rf, taken together with the atom to which they are attached, form a 3- to 7-membered heterocycloalkyl, wherein each hydrogen atom in C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, C1-C6alkylene-C6-C10 aryl, 5- to 10-membered heteroaryl, and C1-C6alkylene-5- to 10-membered heteroaryl is independently optionally substituted by deuterium, halogen, C1-C6alkyl, C1-C6haloalkyl, -OH, -OC1-C6alkyl, -OC(O)- (H or C1-C6alkyl), -OC(O)N(H or C1-C6alkyl)2, -OC(O)N(C2-C6alkylene), -OS(O)-(H or C1-C6alkyl), -OS(O)2-(H or C1-C6alkyl), -OS(O)N(H or C1-C6alkyl)2, -OS(O)N(C2-C6alkylene), -OS(O)2N(H or C1-C6alkyl)2, -OS(O)2N(C2-C6alkylene), -S(H or C1-C6alkyl), -S(O)(H or C1-C6alkyl), -S(O)2(H or C1-C6alkyl), -S(O)N(H or C1-C6alkyl)2, -S(O)N(C2-C6alkylene), -S(O)2N(H or C1-C6alkyl)2, -S(O)2N(C2-C6alkylene), -N(H or C1-C6alkyl)2, -N(C2-C6alkylene), -N(H or C1-C6alkyl)C(O)-(H or C1-C6alkyl), -N(H or C1-C6alkyl)C(O)O(H or C1-C6alkyl), -N(H or C1-C6alkyl)C(O)N(H or C1-C6alkyl)2, -N(H or C1-C6alkyl)C(O)N(C2-C6alkylene), -N(H or C1-C6alkyl)S(O)-(H or C1-C6alkyl), -N(H or C1-C6alkyl)S(O)2(H or C1-C6alkyl), -N(H or C1-C6alkyl)S(O)N(H or C1-C6alkyl)2, -N(H or C1-C6alkyl)S(O)N(C2-C6alkylene), -N(H or C1-C6alkyl)S(O)2N(H or C1-C6alkyl)2, -N(H or C1-C6alkyl)S(O)2N(C2-C6alkylene), -C(O)-(H or C1-C6alkyl), -C(O)O(H or C1-C6alkyl), -C(O)N(C2-C6alkylene), -P(H or C1-C6alkyl)2, -P(C2-C6alkylene), -P(O)(H or C1-C6alkyl)2, -P(O)(C2-C6alkylene), -P(O)2(H or C1-C6alkyl)2, -P(O)2(C2-C6alkylene), -P(O)N(H or C1-C6alkyl)2, -P(O)N(C2-C6alkylene), -P(O)2N(H or C1-C6alkyl)2, -P(O)2N(C2-C6alkylene), -P(O)O(H or C1-C6alkyl), -P(O)2O(H or C1-C6alkyl), -CN, or -NO2; m is 0, 1, 2, or 3; n is 0, 1, 2, or 3; p is 1, 2, 3, or 4; and q is 1, 2, or 3; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
2. The compound of claim 1, having the formula IIII wherein each “ ” is independently a carbon-carbon single bond or a carbon-carbon double bond; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
3. The compound of claim 1 or 2, having the formula IIIwherein each “ ” is independently a carbon-carbon single bond or a carbon-carbon double bond; X1, X2, and X3are each independently -O-, -S-, =C(H)-, =C(R1)-, -N(H)-, -N(R1)- or =N-, provided that at least one of X1, X2, and X3is not =C(H)-, or =C(R1)-; and / or Y1, Y2, and Y3are each independently -O-, -S-, =C(H)-, =C(R2)-, -N(H)-, -N(R2)- or =N-, provided that at least one of Y1, Y2, and Y3is not =C(H)-, or =C(R2)-; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
4. The compound of claim 3, having the formula IVor a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
5. The compound of claim 3 or 4, wherein X2is =N- or -N(R1)-, X1and X3are each independently -O-, -S-, =C(H)-, =C(R1)-, -N(H)-, or -N(R1)-; and / or Y2is =N-, Y1and Y3are each independently -O-, -S-, =C(H)-, =C(R2)-, -N(H)-, or -N(R2)-; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
6. The compound of any one of claims 1 to 4, wherein: ring A is selected from the group consisting ofwherein each “ ” represents a point of covalent attachment; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
7. The compound of any one of the preceding claims, wherein ring A is selected from the group consisting of wents a point of covalent attachment; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
8. The compound of any one of the preceding claims, wherein ring A is selected from the group consisting ofwherein each “ ” represents a point of covalent attachment; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
9. The compound of any one of claims 1 to 4 or 6, wherein ring B is selected from the group consisting of, wherein each“ ” represents a point of covalent attachment; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
10. The compound of any one of the preceding claims, wherein ring B is selected from the group consisting ofwherein each“ ” represents a point of covalent attachment; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
11. The compound of any one of the preceding claims, wherein p is 2 or 3, and the portionis an ethylene or propylene, wherein each R3and R4is independently H, halogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, -ORa, -OC(O)Ra, -OC(O)NRaRb, -OS(O)Ra, -OS(O)2Ra, -SRa, -S(O)Ra, -S(O)2Ra, -S(O)NRaRb, -S(O)2NRaRb, -OS(O)NRaRb, -OS(O)2NRaRb, -NRaRb, -NRaC(O)Rb, -NRaC(O)ORb, -NRaC(O)NRaRb, -NRaS(O)Rb, -NRaS(O)2Rb, -NRaS(O)NRaRb, -NRaS(O)2NRaRb, -C(O)Ra, -C(O)ORa, -C(O)NRaRb, -PRaRb, -P(O)RaRb, -P(O)2RaRb, -P(O)NRaRb, -P(O)2NRaRb, -P(O)ORa, -P(O)2ORa, -CN, or -NO2; or at least one instance of R3and R4, taken together with the carbon or carbons to which they are attached, combine to form C3-C6cycloalkyl or 4- to 7-membered heterocycloalkyl, wherein each hydrogen atom in C3-C6cycloalkyl and 4- to 7-membered heterocycloalkyl is independently optionally substituted by -ORe, -OC(O)Re, -OC(O)NReRf, -OS(O)Re, -OS(O)2Re, -OS(O)NReRf, -OS(O)2NReRf, -SRe, -S(O)Re, -S(O)2Re, -S(O)NReRf, -S(O)2NReRf, -NReRf, -NReC(O)Rf, -NReC(O)ORf, -NReC(O)NReRf, -NReS(O)Rf, -NReS(O)2Rf, -NReS(O)NReRf, -NReS(O)2NReRf, -C(O)Re, -C(O)ORe, -C(O)NReRf, -PReRf, -P(O)ReRf, -P(O)2ReRf, -P(O)NReRf, -P(O)2NReRf, -P(O)ORe, -P(O)2ORe, -CN, or -NO2; or R7and one instance of R3or R4, taken together with the atoms to which they are attached, combine to form 4- to 7-membered heterocycloalkyl, wherein each hydrogen atom in 4- to 7-membered heterocycloalkyl formed is independently optionally substituted by -ORe, -OC(O)Re, -OC(O)NReRf, -OS(O)Re, -OS(O)2Re, -OS(O)NReRf, -OS(O)2NReRf, -SRe, -S(O)Re, -S(O)2Re, -S(O)NReRf, -S(O)2NReRf, -NReRf, -NReC(O)Rf, -NReC(O)ORf, -NReC(O)NReRf, -NReS(O)Rf, -NReS(O)2Rf, -NReS(O)NReRf, -NReS(O)2NReRf, -C(O)Re, -C(O)ORe, -C(O)NReRf, -PReRf, -P(O)ReRf, -P(O)2ReRf, -P(O)NReRf, -P(O)2NReRf, -P(O)ORe, -P(O)2ORe, -CN, or -NO2; and each “” represents a point of covalent attachment; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
12. The compound of any one of the preceding claims, wherein one R3is C1-C6alkyl, wherein each hydrogen atom in C1-C6alkyl is independently optionally substituted by deuterium, halogen, C1-C6alkyl, C1-C6haloalkyl, -ORe, -OC(O)Re, -OC(O)NReRf, -OS(O)Re, -OS(O)2Re, -OS(O)NReRf, -OS(O)2NReRf, -SRe, -S(O)Re, -S(O)2Re, -S(O)NReRf, -S(O)2NReRf, -NReRf, -NReC(O)Rf, -NReC(O)ORf, -NReC(O)NReRf, -NReS(O)Rf, -NReS(O)2Rf, -NReS(O)NReRf, -NReS(O)2NReRf, -C(O)Re, -C(O)ORe, -C(O)NReRf, -PReRf, -P(O)ReRf, -P(O)2ReRf, -P(O)NReRf, -P(O)2NReRf, -P(O)ORe, -P(O)2ORe, -CN, or -NO2; and / or two R3and R4, taken together with the carbon or carbons to which they are attached, combine to form C3-C6cycloalkyl or 4- to 7-membered heterocycloalkyl, wherein each hydrogen atom in C3-C6cycloalkyl and 4- to 7-membered heterocycloalkyl is independently optionally substituted by-ORe, -OC(O)Re, -OC(O)NReRf, -OS(O)Re, -OS(O)2Re, -OS(O)NReRf, -OS(O)2NReRf, -SRe, -S(O)Re, -S(O)2Re, -S(O)NReRf, -S(O)2NReRf, -NReRf, -NReC(O)Rf, -NReC(O)ORf, -NReC(O)NReRf, -NReS(O)Rf, -NReS(O)2Rf, -NReS(O)NReRf, -NReS(O)2NReRf, -C(O)Re, -C(O)ORe, -C(O)NReRf, -PReRf, -P(O)ReRf, -P(O)2ReRf, -P(O)NReRf, -P(O)2NReRf, -P(O)ORe, -P(O)2ORe, -CN, or -NO2; and / or R7and one instance of R3or R4and, taken together with the atoms to which they are attached, combine to form a 4- to 7-membered heterocycloalkyl, wherein each hydrogen atom in 4- to 7-membered heterocycloalkyl is independently optionally substituted by -ORe, -OC(O)Re, -OC(O)NReRf, -OS(O)Re, -OS(O)2Re, -OS(O)NReRf, -OS(O)2NReRf, -SRe, -S(O)Re, -S(O)2Re, -S(O)NReRf, -S(O)2NReRf, -NReRf, -NReC(O)Rf, -NReC(O)ORf, -NReC(O)NReRf, -NReS(O)Rf, -NReS(O)2Rf, -NReS(O)NReRf, -NReS(O)2NReRf, -C(O)Re, -C(O)ORe, -C(O)NReRf, -PReRf, -P(O)ReRf, -P(O)2ReRf, -P(O)NReRf, -P(O)2NReRf, -P(O)ORe, -P(O)2ORe, -CN, or -NO2; and any remaining R3and R4are H or deuterium; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
13. The compound of any one of the preceding claims, wherein one R3is C1-C6alkyl, wherein each hydrogen atom in C1-C6alkyl is independently optionally substituted by deuterium, halogen, C1-C6alkyl, C1-C6haloalkyl, -ORe, -OC(O)Re, -OC(O)NReRf, -OS(O)Re, -OS(O)2Re, -OS(O)NReRf, -OS(O)2NReRf, -SRe, -S(O)Re, -S(O)2Re, -S(O)NReRf, -S(O)2NReRf, -NReRf, -NReC(O)Rf, -NReC(O)ORf, -NReC(O)NReRf, -NReS(O)Rf, -NReS(O)2Rf, -NReS(O)NReRf, -NReS(O)2NReRf, -C(O)Re, -C(O)ORe, -C(O)NReRf, -PReRf, -P(O)ReRf, -P(O)2ReRf, -P(O)NReRf, -P(O)2NReRf, -P(O)ORe, -P(O)2ORe, -CN, or -NO2; and / or R7and one instance of R3or R4taken together with the atoms to which they are attached, combine to form 4- to 7- membered heterocycloalkyl, wherein each hydrogen atom in 4- to 7-membered heterocycloalkyl is independently optionally substituted by -ORe, -OC(O)Re, -OC(O)NReRf, -OS(O)Re, -OS(O)2Re, -OS(O)NReRf, -OS(O)2NReRf, -SRe, -S(O)Re, -S(O)2Re, -S(O)NReRf, -S(O)2NReRf, -NReRf, -NReC(O)Rf, -NReC(O)ORf, -NReC(O)NReRf, -NReS(O)Rf, -NReS(O)2Rf, -NReS(O)NReRf, -NReS(O)2NReRf, -C(O)Re, -C(O)ORe, -C(O)NReRf, -PReRf, -P(O)ReRf, -P(O)2ReRf, -P(O)NReRf, -P(O)2NReRf, -P(O)ORe, -P(O)2ORe, -CN, or -NO2; and any remaining R3and R4are H or deuterium; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
14. The compound of any one of the preceding claims, wherein one instance of R3is C1-C6alkyl; and any remaining R3and R4are H or deuterium; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
15. The compound of any one of the preceding claims, wherein one instance of R3is C1-C6alkyl; R7and one instance of R4, taken together with the atoms to which they are attached, combine to form a 4- to 7-membered heterocycloalkyl; and any remaining R3and R4are H or deuterium; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
16. The compound of any one of the preceding claims, wherein one instance of R3is methyl, and any remaining R3and R4are H or deuterium; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
17. The compound of any one of the preceding claims, wherein R7is H, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)Rc; or R7and one instance of R3or R4, taken together with the atoms to which they are attached, combine to form 4- to 7-membered heterocycloalkyl; wherein each hydrogen atom in C1-C6alkyl, C3-C6cycloalkyl, and 4- to 7-membered heterocycloalkyl is independently optionally substituted by -ORc, -OC(O)Rc, -OC(O)NRcRd, -OC(=NRd)NRcRd, -OS(O)Rc, -OS(O)2Rc, -OS(O)NRcRd, -OS(O)2NRcRd, -SRc, -S(O)Rc, -S(O)2Rc, -S(O)NRcRd, -S(O)2NRcRd, -NRcRd, -NRcC(O)Rd, -N(C(O)Rc)(C(O)Rd), -NRcC(O)ORd, -NRcC(O)NRcRd, -NRcC(=NRd)NRcRd, -NRcS(O)Rd, -NRcS(O)2Rd, -NRcS(O)NRcRd, -NRcS(O)2NRcRd, -C(O)Rc, -C(O)ORc, -C(O)NRcRd, -C(=NRd)NRcRd, -PRcRd, -P(O)RcRd, -P(O)2RcRd, -P(O)NRcRd, -P(O)2NRcRd, -P(O)ORc, -P(O)2ORc, -CN, or -NO2; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
18. The compound of any one of the preceding claims, wherein the portion i,” represents a point of covalent attachment, and each hydrogen is independently optionally substituted with deuterium; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
19. The compound of any one of the preceding claims, wherein R5and R6are each H; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
20. The compound of any one of the preceding claims, wherein the portionis of the formula,, nt, and each hydrogen is independently optionally substituted with deuterium; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
21. The compound of any one of the preceding claims, wherein R8is H or C1-C6alkyl;or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
22. The compound of any one of the preceding claims, wherein R9is H, deuterium, halogen, C1-C6alkyl, or -ORa, wherein each hydrogen atom in C1-C6alkyl is independently optionally substituted with deuterium; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
23. The compound of any one of the preceding claims, wherein R9is H, deuterium, halogen, -OCH3, -CH3, or -CD3; or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
24. The compound of claim 1, selected from the group consisting of,or 25.,,or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof.
26. A pharmaceutical composition comprising a compound of any one of the preceding claims, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, and optionally one or more excipients.
27. A method of treating disease in a subject comprising, administering a therapeutically effective amount of a compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, or a pharmaceutical composition of claim 26.
28. A compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, for use in a method of treating disease in a subject.
29. Use of a compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt, solvate, hydrate, or cocrystal thereof, in the manufacture of a medicament for the treatment of disease in a subject.
